Treatment Program for Anemia in AIDS Patients

N/ACompletedNCT00002022

R W Johnson Pharmaceutical Research Institute

Overview

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

HIV Infections Cytopenias

Interventions

Epoetin alfaDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Life expectancy \< 3 months. * = or \< grade 4 performance score. * AIDS-related dementia. * Uncontrolled hypertension. * Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients with the following are excluded: * Life expectancy \< 3 months. * = or \< grade 4 performance score. * AIDS-related dementia. * Uncontrolled hypertension. * Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients must have: * A clinical diagnosis of AIDS. * Hematocrit \< 30 percent. * Endogenous serum erythropoietin level = or \< 500 U/ml. * A life expectancy = or \> 3 months. * \> Grade 4 performance score.

Locations (1)

R W Johnson Pharmaceutical Research Institute

Raritan, New Jersey, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.